

## Preliminary Scientific Programme

### Day 1 – Inflammatory Arthritis (Thursday 17 February 2011)

#### Plenary lectures

- Epidemiology of Early Arthritis
- Diagnostic Criteria for Early Arthritis
- Management of Early Arthritis

#### Plenary lectures/ Achievements in Rheumatology

- The history of TNF inhibition
- The history of anti CCP antibodies
- Management of Rheumatoid Arthritis, a comparison between 1980 and 2010

#### Round Tables

- How Big is the Window of Opportunity in RA?

#### Lectures in Clinimetrics

- The Assessment of (Rheumatoid) Arthritis in Clinical Trials and Daily Practice
- Remission Criteria: Why Bother?

#### Lectures

- Rheumatoid Vasculitis
- Interstitial Lung Disease

#### Concurrent Session

- The role of Different Imaging Tools in daily clinical practice: Diagnosis, prognosis and monitoring
  - Conventional X-rays – MRI – Ultrasound - Future techniques

#### Workshops

- Clinical Assessment of disease activity
- Assessment of the Modified Shap Score
- Ultrasound for Dummies

#### Clinical Problem Solving

- Should we always use combination treatment in patients with RA?
- Treat to target or target to treat? Is personalised medicine already feasible?
- Management of Rheumatoid Arthritis/ The management of pregnancy in RA

#### Miscellaneous Hot Topics

- Quality indicators in RA
- What to do if all regular treatment options have failed?
- Debate: Remission is a realistic goal in RA: yes or no

#### Clinical Problems/ Meet the expert

- How to improve the compliance of my patients
- How to apply tight control in Daily Practice
- Optimal use of corticosteroids in the management of RA
- Rituximab dosing: on demand or fixed?
- Is there a rationale for a certain sequence/ choice of Biological Response Modifier?
- After failure of one anti TNF: what to do?

## Preliminary Scientific Programme

### Day 2 – Systemic Autoimmunity (Friday 18 February 2011)

#### Plenary lectures

- Systemic Autoimmunity
- Novel Concepts in the Pathogenesis of Scleroderma
- Mining the Biochemistry of the immune cell for the development of novel targets and biomarkers
- Mining complement for the development of SLE Biomarkers
- Genetics of Human Lupus

#### Lectures in Renal Disease

- Treatment challenges
- Renal biomarkers
- SLE Nephropathology, a Tutorial

#### Lectures in CNS Disease

- Mechanisms of brain injury
- Management of CNS disease
- CNS Vasculitis

#### Lectures in APLS

- Mechanisms of thrombosis
- Management of APLS
- APLS is a separate entity or a brother of SLE?

#### Lectures

- Behcet's Disease
- New concepts in Angiitis
- Asia and new syndrome of adjuvant induced autoimmunity
- Trials of Biologics in Lupus
- Scleroderma
- Lung Transplant in CTD
- Pregnancy: Risks and Mechanisms
- Management of pregnancy in SLE
- Neonatal Lupus

## Preliminary Scientific Programme

### Day 3 – Co-morbidity (Saturday 19 February 2011)

#### Plenary lectures

- Epidemiology of Cardiovascular co-morbidity in RA and SLE
- Mechanisms of CVD morbidity/ mortality in SLE: Classical CVD risk vs SLE-specific factors
- Mechanisms of CVD morbidity/ mortality in RA: Classical CVD risk vs RA-specific factors
- Pathogenesis of vasculopathies in inflammatory connective tissues diseases

#### Clinical Problems

- A common sense approach to the assessment and management of CVD in RA

#### Lectures in Malignancy

- Should we screen patients presenting with rheumatological complaints for malignancy - and how?
- Malignancy in RA: an overview and current trends
- Biologics and malignancy risk in RA
- Can I use a biologic drug in a patient with a history of malignancy?

#### Lectures in Infection

- Infection risk with the use of biologics in RA
- Management of infection in the immuno-compromised patient
- Hepatitis and anti-TNFs: do's and don't's
- Neutropaenia with biologics

#### Lectures in Psychosocial Co-morbidity

- The Psychosocial impact of Rheumatic Disease
- Identifying and treating depression in chronic musculoskeletal disease
- Do psychosocial interventions work in Rheumatoid Arthritis?
- Is fatigue important – and what can we do about it?
- Psychosocial outcomes in the biologics era

#### Clinical Problem Solving in Secondary Osteoporosis

- Is there a safe way to use corticosteroids?
- Steroid – induced osteoporosis: mechanisms
- Steroid – induced osteoporosis: assessing risk
- Steroid – induced osteoporosis: prevention and management

#### Clinical Problem Solving in Obesity/ Cachexia in RA

- Rheumatoid cachexia
- Obesity and its implications in RA
- Exercise in RA
- Diet and exercise in RA as part of routine care

#### Clinical Problem Solving

- Methotrexate: pneumonitis and hepatic fibrosis